Label (71610 0936 30)
This is a medication description for Pregabalin 100mg with NDC# 71610-096-30. It may be related to dosage or prescription information.*
Pregabalin Capsule
Product Images NDC 71610-936
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-936). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Figure 1 (Pregabalin Fig01)
Figure 2 (Pregabalin Fig02)
This text is not-readable.*
Figure 3 (Pregabalin Fig03)
Figure 4 (Pregabalin Fig04)
This appears to be a record showing the progress of patients under treatment. The document indicates the use of Pregabalin at different dosages three times a day and a placebo. The codes related to numbers seem to reflect different measurements or assessments of patient improvement in pain from the baseline.*
Figure 5 (Pregabalin Fig05)
This text appears to be a comparison between the effectiveness of Fregabalin (100mg three times a day) and Pregabalin (80mg three times a day) in comparison to a placebo. It also mentions the improvement of patients and the percentage of improvement in pain from baseline. The data seems to show a comparison of these medications in terms of pain relief.*
Figure 6 (Pregabalin Fig06)
This document appears to be a comparison of different studies involving the use of placebo and varying doses of a substance (possibly a medication). The text mentions different dosage levels such as 50mg/day, 150mg/day, 300mg/day, and 600mg/day. It also indicates that there is a statistically significant difference compared to the placebo group. The study designs are labeled as E1 and E3.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
This information provides data on the percentage of patients who showed improvement in pain levels when treated with different doses of Pregabalin daily and with placebo. The graph shows the percent of patients improved over the baseline pain levels for Pregabalin at 300mg and 450mg doses, as well as for a placebo group. The results could be used to evaluate the effectiveness of different dosage levels of Pregabalin in managing pain.*
Figure 10 (Pregabalin Fig09)
The text provides a list of estimated percentages of subjects without LTR (Likely to Recommend) over different days in a study. The data shows the comparison between Progabain and Placebo groups. The percentages range from 0% to 100% and are tracked over a time period of 0 to 180 days. The information offers insight into the effectiveness or outcomes of the treatments being studied.*
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
This text provides information on the percentage of subjects that improved over the course of the study, possibly related to a medication such as Pregabalin compared to a placebo. The data shows percentages at different time points or intervals, possibly representing the improvement from baseline to week 16. The numbers listed are in the range of 100 to 280, with specific values such as 210, 220, 230, 240, 250, 260, and 270 mentioned. The text seems to be a tabular representation of the efficacy or response rates seen in the study.*
Figure 13 (Pregabalin Fig13)
This is a tabular data showing responder rates for different doses of a drug compared to a placebo. The responder rate is expressed as a percentage for each dose. The text contains percentages for different doses, with the highest responder rate being 40.6%. Additionally, there is a mention of two doses of the drug, placebo, and corresponding responder rates.*
Cockcroft And Gault Equation (Pregabalin Formula)
This description provides a formula for calculating creatinine clearance (CLcr) in adults. The formula involves subtracting the age in years from 140, then multiplying by the weight in kilograms. For female patients, the result is further multiplied by 0.85. The final step is multiplying the result obtained by 72 and by the serum creatinine level in mg/dL. This formula is commonly used in clinical settings to estimate renal function.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
